7 research outputs found
Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or
hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance
(AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with
chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality
were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs
with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were
resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant
to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance
in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly
associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant
S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia
and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU
admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need
of ICU admission were significantly associated with mortality. Center-level variation showed a
greater impact on AR, while patient-level variation had more effect on ICU admission and mortality.
Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI.
Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a
significant role for the treating center too. The significant evidence of center-level variations on AR,
ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection
control programs
Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality.
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance (AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need of ICU admission were significantly associated with mortality. Center-level variation showed a greater impact on AR, while patient-level variation had more effect on ICU admission and mortality. Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI. Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a significant role for the treating center too. The significant evidence of center-level variations on AR, ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection control programs
Antibiotic resistant bloodstream infections in pediatric patients receiving chemotherapy or hematopoietic stem cell transplant: factors associated with development of resistance, intensive care admission and mortality
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance (AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need of ICU admission were significantly associated with mortality. Center-level variation showed a greater impact on AR, while patient-level variation had more effect on ICU admission and mortality. Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI. Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a significant role for the treating center too. The significant evidence of center-level variations on AR, ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection control programs
Recommended from our members
Prevalence of deleterious variants in MC3R in patients with constitutional delay of growth and puberty.
CONTEXT: The melanocortin 3 receptor (MC3R) has recently emerged as a critical regulator of pubertal timing, linear growth and the acquisition of lean mass in humans and mice. In population-based studies, heterozygous carriers of deleterious variants in MC3R report a later onset of puberty than non-carriers. However, the frequency of such variants in patients who present with clinical disorders of pubertal development is currently unknown. OBJECTIVE: To determine whether deleterious MC3R variants are more frequently found in patients clinically presenting with constitutional delay of growth and puberty (CDGP) or normosmic idiopathic hypogonadotropic hypogonadism (nIHH). DESIGN, SETTING AND PARTICIPANTS: We examined the sequence of MC3R in 362 adolescents with a clinical diagnosis of CDGP and 657 patients with nIHH, experimentally characterised the signalling properties of all non-synonymous variants found and compared their frequency to that in 5774 controls from a population-based cohort. Additionally, we established the relative frequency of predicted deleterious variants in individuals with self-reported delayed vs normally timed menarche/voice breaking in the UK Biobank cohort. RESULTS: MC3R loss-of-function variants were infrequent but overrepresented in patients with CDGP (8/362 (2.2%), OR = 4.17, p = 0.001). There was no strong evidence of overrepresentation in patients with nIHH (4/657 (0.6%), OR = 1.15, p = 0.779). In 246,328 women from UK Biobank, predicted deleterious variants were more frequently found in those self-reporting delayed (≥16 years) vs normal age at menarche (OR = 1.66, p = 3.90E-07). CONCLUSIONS: We have found evidence that functionally damaging variants in MC3R are overrepresented in individuals with CDGP but are not a common cause of this phenotype
Prevalence of deleterious variants in MC3R in patients with constitutional delay of growth and puberty
Prevalence of Deleterious Variants in MC3R in Patients With Constitutional Delay of Growth and Puberty
Context The melanocortin 3 receptor (MC3R) has recently emerged as a critical regulator of pubertal timing, linear growth, and the acquisition of lean mass in humans and mice. In population-based studies, heterozygous carriers of deleterious variants in MC3R report a later onset of puberty than noncarriers. However, the frequency of such variants in patients who present with clinical disorders of pubertal development is currently unknown. Objective This work aimed to determine whether deleterious MC3R variants are more frequently found in patients clinically presenting with constitutional delay of growth and puberty (CDGP) or normosmic idiopathic hypogonadotropic hypogonadism (nIHH). Methods We examined the sequence of MC3R in 362 adolescents with a clinical diagnosis of CDGP and 657 patients with nIHH, experimentally characterized the signaling properties of all nonsynonymous variants found and compared their frequency to that in 5774 controls from a population-based cohort. Additionally, we established the relative frequency of predicted deleterious variants in individuals with self-reported delayed vs normally timed menarche/voice-breaking in the UK Biobank cohort. Results MC3R loss-of-function variants were infrequent but overrepresented in patients with CDGP (8/362 [2.2%]; OR = 4.17; P = .001). There was no strong evidence of overrepresentation in patients with nIHH (4/657 [0.6%]; OR = 1.15; P = .779). In 246 328 women from the UK Biobank, predicted deleterious variants were more frequently found in those self-reporting delayed (aged ≥16 years) vs normal age at menarche (OR = 1.66; P = 3.90E-07). Conclusion We have found evidence that functionally damaging variants in MC3R are overrepresented in individuals with CDGP but are not a common cause of this phenotype.Fil: Duckett, Katie. Addenbrooke’s Hospital; Reino UnidoFil: Williamson, Alice. Addenbrooke’s Hospital; Reino UnidoFil: Kincaid, John W. R.. Addenbrooke’s Hospital; Reino UnidoFil: Rainbow, Kara. Addenbrooke’s Hospital; Reino UnidoFil: Corbin, Laura J.. University of Bristol; Reino UnidoFil: Martin, Hilary C.. Wellcome Sanger Institute; Reino UnidoFil: Eberhardt, Ruth Y.. Wellcome Sanger Institute; Reino UnidoFil: Huang, Qin Qin. Wellcome Sanger Institute; Reino UnidoFil: Hurles, Matthew E.. Wellcome Sanger Institute; Reino UnidoFil: He, Wen. Boston Children’s Hospital; Estados UnidosFil: Brauner, Raja. Umr - S1134 Biologie Integree Du Globule Rouge ; Universite de Paris;Fil: Delaney, Angela. St. Jude Children’s Research Hospital; Estados UnidosFil: Dunkel, Leo. Barts & the London Medical School; Reino UnidoFil: Grinspon, Romina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". Gobierno de la Ciudad de Buenos Aires. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". FundaciĂłn de EndocrinologĂa Infantil. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada"; ArgentinaFil: Hall, Janet E. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". Gobierno de la Ciudad de Buenos Aires. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". FundaciĂłn de EndocrinologĂa Infantil. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada"; ArgentinaFil: Hirschhorn, Joel N.. Public Health Service. National Institute Of Health; Estados UnidosFil: Howard, Sasha R.. Queen Mary University of London; Reino UnidoFil: Latronico, Ana C.. No especifĂca;Fil: Jorge, Alexander A. L.. No especifĂca;Fil: McElreavey, Ken. Universite de Paris; FranciaFil: Mericq, VerĂłnica. Universidad de Chile; ChileFil: Merino, Paulina M.. Universidad de Chile; ChileFil: Palmert, Mark R.. University of Toronto; CanadáFil: Plummer, Lacey. Massachusetts General Hospital Harvard; Estados UnidosFil: Rey, Rodolfo Alberto. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". Gobierno de la Ciudad de Buenos Aires. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". FundaciĂłn de EndocrinologĂa Infantil. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada"; ArgentinaFil: Rezende, RaĂssa C.. No especifĂca;Fil: Seminara, Stephanie B.. Massachusetts General Hospital Harvard; Estados UnidosFil: Salnikov, Kathryn. Massachusetts General Hospital Harvard; Estados UnidosFil: Banerjee, Indraneel. Royal Manchester Children’s Hospital; Reino UnidoFil: Lam, Brian Y. H.. Wellcome-MRC Institute of Metabolic Science; Reino UnidoFil: Perry, John R. B.. Wellcome-MRC Institute of Metabolic Science; Reino UnidoFil: Timpson, Nicholas J.. University of Bristol; Reino UnidoFil: Clayton, Peter. Royal Manchester Children’s Hospital; Reino UnidoFil: Chan, Yee Ming. Boston Children’s Hospital; Estados UnidosFil: Ong, Ken K.. University of Cambridge; Estados UnidosFil: O’Rahilly, Stephen. University of Cambridge; Estados Unido
Delayed Puberty-Phenotypic Diversity, Molecular Genetic Mechanisms, and Recent Discoveries.
This review presents a comprehensive discussion of the clinical condition of delayed puberty, a common presentation to the pediatric endocrinologist, which may present both diagnostic and prognostic challenges. Our understanding of the genetic control of pubertal timing has advanced thanks to active investigation in this field over the last two decades, but it remains in large part a fascinating and mysterious conundrum. The phenotype of delayed puberty is associated with adult health risks and common etiologies, and there is evidence for polygenic control of pubertal timing in the general population, sex-specificity, and epigenetic modulation. Moreover, much has been learned from comprehension of monogenic and digenic etiologies of pubertal delay and associated disorders and, in recent years, knowledge of oligogenic inheritance in conditions of GnRH deficiency. Recently there have been several novel discoveries in the field of self-limited delayed puberty, encompassing exciting developments linking this condition to both GnRH neuronal biology and metabolism and body mass. These data together highlight the fascinating heterogeneity of disorders underlying this phenotype and point to areas of future research where impactful developments can be made